9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.